Business Description
Anuh Pharma Ltd
ISIN : INE489G01022
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.7 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.17 | |||||
Interest Coverage | 115.89 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 7.51 | |||||
Beneish M-Score | -1.76 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.4 | |||||
3-Year EBITDA Growth Rate | 16.5 | |||||
3-Year EPS without NRI Growth Rate | 31.6 | |||||
3-Year Book Growth Rate | 15.2 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 36.18 | |||||
9-Day RSI | 46.83 | |||||
14-Day RSI | 51.84 | |||||
6-1 Month Momentum % | -12.43 | |||||
12-1 Month Momentum % | 31.86 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.43 | |||||
Quick Ratio | 1.88 | |||||
Cash Ratio | 0.4 | |||||
Days Inventory | 56.98 | |||||
Days Sales Outstanding | 99.67 | |||||
Days Payable | 92.9 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.16 | |||||
Dividend Payout Ratio | 0.25 | |||||
Forward Dividend Yield % | 1.16 | |||||
5-Year Yield-on-Cost % | 1.16 | |||||
Shareholder Yield % | 0.79 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 25.47 | |||||
Operating Margin % | 9.93 | |||||
Net Margin % | 9.22 | |||||
FCF Margin % | 1.24 | |||||
ROE % | 20.81 | |||||
ROA % | 13.84 | |||||
ROIC % | 20.21 | |||||
ROC (Joel Greenblatt) % | 43.89 | |||||
ROCE % | 26.63 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 18.31 | |||||
PE Ratio without NRI | 21.27 | |||||
Shiller PE Ratio | 28.74 | |||||
PEG Ratio | 0.98 | |||||
PS Ratio | 1.69 | |||||
PB Ratio | 3.56 | |||||
Price-to-Tangible-Book | 3.57 | |||||
Price-to-Free-Cash-Flow | 136.6 | |||||
Price-to-Operating-Cash-Flow | 83.58 | |||||
EV-to-EBIT | 13.71 | |||||
EV-to-EBITDA | 12.37 | |||||
EV-to-Revenue | 1.63 | |||||
EV-to-FCF | 131.76 | |||||
Price-to-Projected-FCF | 3.2 | |||||
Price-to-Median-PS-Value | 1.12 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.01 | |||||
Price-to-Graham-Number | 1.84 | |||||
Price-to-Net-Current-Asset-Value | 5.89 | |||||
Earnings Yield (Greenblatt) % | 7.29 | |||||
FCF Yield % | 0.73 | |||||
Forward Rate of Return (Yacktman) % | 20.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Anuh Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₹) | 6,398.541 | ||
EPS (TTM) (₹) | 11.77 | ||
Beta | 0.57 | ||
Volatility % | 41.43 | ||
14-Day RSI | 51.84 | ||
14-Day ATR (₹) | 8.887484 | ||
20-Day SMA (₹) | 217.91 | ||
12-1 Month Momentum % | 31.86 | ||
52-Week Range (₹) | 145.65 - 265 | ||
Shares Outstanding (Mil) | 50.11 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Anuh Pharma Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Anuh Pharma Ltd Stock Events
Event | Date | Price(₹) | ||
---|---|---|---|---|
No Event Data |
Anuh Pharma Ltd Frequently Asked Questions
What is Anuh Pharma Ltd(BOM:506260)'s stock price today?
When is next earnings date of Anuh Pharma Ltd(BOM:506260)?
Does Anuh Pharma Ltd(BOM:506260) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |